Frans Van de Werf

Frans Van de Werf's AcademicInfluence.com Rankings

Frans Van de Werf

Philosophy

#3974

World Rank

#6326

Historical Rank

Logic

#1539

World Rank

#2316

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Frans Van de Werf Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Frans Van de Werf is a Belgian cardiologist at the University Hospital Leuven and Professor Emeritus, Department of Cardiovascular Sciences, Katholieke Universiteit Leuven. He was the chair of the university hospital's cardiovascular medicine department until 2011.

(See a Problem?)

Frans Van de Werf's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. (2000) (4196)
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. (1993) (3530)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. (2003) (2366)
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008) (2081)
Predictors of hospital mortality in the global registry of acute coronary events. (2003) (2077)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study (2012) (2002)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. (2015) (1907)
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) (2006) (1396)
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. (2003) (1374)
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. (2000) (868)
Acute Coronary Care in the Elderly, Part I. Non–ST-Segment–Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology (2007) (859)
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. (2005) (773)
Dabigatran versus warfarin in patients with mechanical heart valves. (2013) (760)
Evolving therapies for myocardial ischemia/reperfusion injury. (2015) (730)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. (1999) (709)
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. (2004) (677)
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. (2005) (637)
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. (2005) (621)
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. (2006) (592)
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION (ENDING) (2009) (590)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial (1999) (585)
Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease (2001) (546)
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. (2011) (540)
Sex differences in mortality following acute coronary syndromes. (2009) (483)
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. (2007) (437)
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. (1999) (424)
Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). (2010) (422)
Acute Coronary Care in the Elderly, Part II: ST-Segment–Elevation Myocardial Infarction A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology (2007) (421)
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. (2013) (418)
Early versus delayed, provisional eptifibatide in acute coronary syndromes. (2009) (406)
Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. (1988) (390)
Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE) (2005) (356)
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. (1984) (355)
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. (2007) (350)
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. (1995) (341)
Heart rate variability and heart rate in healthy volunteers. Is the female autonomic nervous system cardioprotective? (1998) (337)
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. (1998) (335)
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. (2006) (321)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. (1999) (311)
Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. (1992) (310)
Isolated single coronary artery: a review of 50,000 consecutive coronary angiographies. (1992) (296)
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. (2000) (289)
External validity of clinical trials in acute myocardial infarction. (2007) (282)
Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart (2005) (279)
Enhanced Ca2 Release and Na/Ca Exchange Activity in Hypertrophied Canine Ventricular Myocytes: Potential Link Between Contractile Adaptation and Arrhythmogenesis (2000) (275)
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. (2008) (275)
Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. (2009) (271)
Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial (2002) (265)
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. (1992) (256)
The European Heart Journal: parting thoughts after 6 years of editorship. (2008) (237)
Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy (2001) (233)
ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. (2000) (225)
Cardiomyocyte-Specific Overexpression of Nitric Oxide Synthase 3 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction (2004) (225)
Antiplatelet agents for the treatment and prevention of atherothrombosis. (2011) (220)
Low efficiency of Ca2+ entry through the Na(+)-Ca2+ exchanger as trigger for Ca2+ release from the sarcoplasmic reticulum. A comparison between L-type Ca2+ current and reverse-mode Na(+)-Ca2+ exchange. (1997) (206)
Noninvasive Quantification of the Contractile Reserve of Stunned Myocardium by Ultrasonic Strain Rate and Strain (2001) (200)
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial (2016) (200)
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. (2004) (196)
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. (2016) (195)
Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. (1995) (191)
Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease (2003) (189)
Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events (2006) (187)
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. (2000) (186)
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation (2008) (183)
Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. (1990) (182)
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction (2009) (182)
Coronary artery fistulas in an adult population. (1986) (180)
Defining the Transmurality of a Chronic Myocardial Infarction by Ultrasonic Strain-Rate Imaging: Implications for Identifying Intramural Viability An Experimental Study (2003) (179)
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). (2012) (178)
Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. (1997) (172)
A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. (2001) (171)
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. (2007) (170)
Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. (2014) (170)
Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. (2006) (158)
Thrombolysis for acute myocardial infarction. (1998) (158)
ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial (2008) (156)
Tilt Training: A New Treatment for Recurrent Neurocardiogenic Syncope and Severe Orthostatic Intolerance (1998) (156)
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). (2006) (154)
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. (1999) (153)
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. (2009) (149)
High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. (2011) (149)
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. (2004) (147)
Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries: Results From the GUSTO Trial (1995) (146)
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. (2016) (145)
Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation: Incidence, Predictors, and Outcomes (2002) (144)
Coronary Thrombolysis With Recombinant Staphylokinase in Patients With Evolving Myocardial Infarction (1993) (143)
The analysis of heart rate variability in unrestrained rats. Validation of method and results. (1999) (142)
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. (2009) (140)
Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction ☆ (2006) (140)
Functional recovery of subepicardial myocardial tissue in transmural myocardial infarction after successful reperfusion: an important contribution to the improvement of regional and global left ventricular function. (1999) (138)
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. (2002) (134)
DISCREPANCIES BETWEEN THE EFFECTS OF CORONARY REPERFUSION ON SURVIVAL AND LEFT VENTRICULAR FUNCTION (1989) (133)
Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group. (1995) (130)
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. (2009) (129)
Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study (2005) (127)
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. (2004) (127)
Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. (1993) (126)
Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. (2008) (126)
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. (1993) (125)
Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). (2003) (125)
Right atrial angiographic evaluation of the posterior isthmus: relevance for ablation of typical atrial flutter. (2000) (125)
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. (1986) (124)
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. (2001) (121)
Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. (2010) (118)
INCREASED EXPRESSION OF SYNDECAN-1 PROTECTS AGAINST CARDIAC DILATATION AND DYSFUNCTION AFTER MYOCARDIAL INFARCTION.: PH.5 (2005) (117)
Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion. (2007) (117)
Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. (2003) (116)
Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. (2008) (115)
Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. (1997) (115)
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (115)
Time to Treatment Influences the Impact of ST-Segment Resolution on One-Year Prognosis: Insights From the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Trial (2001) (112)
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. (2009) (111)
Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. (1996) (110)
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. (2003) (109)
Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis (2006) (107)
High Yield Production and Purification of Recombinant Staphylokinase for Thrombolytic Therapy (1994) (107)
Evidence for decreased coronary flow reserve in viable postischemic myocardium. (1990) (104)
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. (2000) (103)
Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. (2008) (100)
Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction. (2010) (96)
Absence of Thrombospondin-2 Causes Age-Related Dilated Cardiomyopathy (2009) (96)
Diastolic properties of the left ventricle in normal adults and in patients with third heart sounds. (1984) (94)
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. (2003) (94)
Medication performance measures and mortality following acute coronary syndromes. (2005) (94)
Long‐Term Follow‐Up Results of Tilt Training Therapy in Patients with Recurrent Neurocardiogenic Syncope (2002) (91)
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. (2005) (89)
Evaluation of the biocompatibility of two new diamond-like stent coatings (Dylyn) in a porcine coronary stent model. (2000) (88)
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context (2003) (87)
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2017) (87)
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro (2005) (84)
A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction (1998) (84)
Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. (2005) (83)
Tilt Training: A Treatment for Malignant and Recurrent Neurocardiogenic Syncope (2000) (81)
Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study (2015) (81)
Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. (2006) (81)
From abstract to impact in cardiovascular research: factors predicting publication and citation (2012) (80)
The genesis of the third and fourth heart sounds. A pressure-flow study in dogs. (1984) (80)
Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. (2015) (80)
Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. (2017) (80)
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. (2005) (79)
[Fourth universal definition of myocardial infarction (2018)]. (2018) (78)
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. (1999) (76)
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. (2000) (76)
Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. (2010) (76)
Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. (2005) (76)
Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics (2004) (76)
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. (2010) (76)
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology. (2011) (76)
Renal function, concomitant medication use and outcomes following acute coronary syndromes. (2005) (75)
Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. (2004) (75)
Detection of regional myocardial dysfunction in patients with acute myocardial infarction using velocity vector imaging. (2008) (73)
ESC guidelines on management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. (2009) (73)
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. (2000) (72)
Overexpression of a Constitutively Active Protein Kinase G Mutant Reduces Neointima Formation and In-Stent Restenosis (2002) (71)
International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. (2003) (71)
The European Heart Journal—the challenge of the next years (2003) (71)
Recombinant Tissue‐Type Plasminogen Activator and Immediate Angioplasty in Acute Myocardial Infarction: One‐Year Follow‐up (1992) (70)
A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Results From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial (2010) (69)
Angina, “Normal” Coronary Angiography, and Vascular Dysfunction: Risk Assessment Strategies (2007) (69)
Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. (2006) (69)
Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. (2010) (67)
A 72 year old woman with ALCAPA (2000) (67)
Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. (2001) (66)
Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes (2012) (66)
Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome (2001) (66)
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. (2002) (64)
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. (2010) (64)
ST–Segment-Elevation Myocardial Infarction Patients Randomized to a Pharmaco-Invasive Strategy or Primary Percutaneous Coronary Intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-Year Mortality Follow-Up (2014) (63)
Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: is there a need for coronary angiography? European Cooperative Study Group. (1993) (63)
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (2017) (62)
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction* (2009) (61)
Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. (2008) (60)
Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. (1994) (60)
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. (2006) (59)
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients (2014) (59)
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. (1997) (57)
Left ventricular quantification with breath-hold MR imaging: comparison with echocardiography (1995) (57)
Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. (2005) (57)
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). (2008) (56)
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype (2018) (55)
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. (2004) (55)
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. (2004) (55)
Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. (2009) (55)
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. (2005) (55)
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. (2016) (54)
Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology (2011) (53)
Different Evolutions in Heart Rate Variability after Heart Transplantation: 10-Year Follow-Up (2004) (53)
Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial. (2006) (53)
Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). (2000) (53)
Spontaneous spinal epidural hematoma associated with thrombolysis and anticoagulation therapy: report of three cases (1998) (53)
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization (2007) (52)
Argatroban and Alteplase in Patients with Acute Myocardial Infarction: The ARGAMI Study (2000) (52)
Association between Cardiac Autonomic Function and Coping Style in Healthy Subjects (1998) (51)
Heart Rate Variability After Cardiac Transplantation in Humans (1996) (51)
Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. (2013) (50)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. (2008) (50)
EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study: rationale, design, and baseline characteristics. (2013) (50)
Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction (2000) (49)
Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. (2004) (49)
RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection (2015) (49)
Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure (2008) (49)
International patterns of dual antiplatelet therapy duration after acute coronary syndromes (2016) (48)
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. (2006) (48)
Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns (2016) (48)
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). (2009) (47)
Determination of left ventricular volume by two-dimensional echocardiography: comparison with magnetic resonance imaging. (1994) (47)
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (2017) (47)
Atrial fibrillation begets atrial fibrillation ... transiently (1998) (47)
High frame rate myocardial integrated backscatter. Does this change our understanding of this acoustic parameter? (2000) (47)
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. (2003) (46)
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. (2007) (46)
Different Patterns of Angiotensin II and Atrial Natriuretic Peptide Secretion in a Sheep Model of Atrial Fibrillation (2001) (46)
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. (2011) (45)
The history of coronary reperfusion. (2014) (45)
Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis. (1990) (45)
Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. (2006) (44)
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. (1998) (44)
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. (2006) (44)
Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. (2013) (44)
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. (2006) (44)
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. (2006) (44)
Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome: An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial (2011) (44)
Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the EARLY ACS Trial (2012) (44)
Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy (2008) (44)
International variation in the use of evidence-based medicines for acute coronary syndromes. (2003) (43)
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). (2014) (43)
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. (2013) (42)
Ablation of post-surgical intra-atrial reentrant tachycardia. Predilection target sites and mapping approach. (2002) (42)
Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 Angiographic Investigators. (1996) (42)
Cardiac Troponins in Acute Coronary Syndromes (1996) (42)
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. (2013) (41)
Holding GUSTO Up to the Light (1994) (41)
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). (2014) (41)
Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score (2019) (40)
Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. (1989) (40)
Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. (2001) (40)
The Clinician as Investigator: Participating in Clinical Trials in the Practice Setting (2004) (40)
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. (2010) (40)
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data (2006) (40)
Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. (2012) (39)
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. (2002) (38)
Reduction in infarct size and enhanced recovery of systolic function after coronary thrombolysis with tissue-type plasminogen activator combined with beta-adrenergic blockade with metoprolol. (1987) (38)
Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. (2006) (38)
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. (2004) (37)
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials (2011) (37)
The mechanism of disappearance of the physiologic third heart sound with age. (1986) (37)
International variation in invasive care of the elderly with acute coronary syndromes. (2006) (37)
Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. (2006) (36)
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. (2004) (36)
Importance of flow/metabolism studies in predicting late recovery of function following reperfusion in patients with acute myocardial infarction. (1997) (36)
Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial (2002) (36)
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). (2003) (36)
Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. (2002) (36)
Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. (2010) (36)
Chlamydia pneumoniae induces neointima formation in coronary arteries of normal pigs. (2003) (35)
The ideal fibrinolytic: can drug design improve clinical results? (1999) (35)
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. (2008) (35)
A Comparison of Systolic Time Intervals Derived from the Central Aortic Pressure and from the External Carotid Pulse Tracing (1975) (34)
Histological correlate of a cardiac magnetic resonance imaged microvascular obstruction in a porcine model of ischemia-reperfusion. (2012) (34)
Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial. (1988) (34)
Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. (2008) (34)
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. (2006) (33)
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. (2003) (33)
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years (2015) (33)
Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. (2003) (33)
Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury (2010) (33)
Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial (2018) (32)
Thrombolysis for Acute Myocardial Infarction Why Is There No Extra Benefit After Hospital Discharge (1995) (32)
Cardiovascular disease on a global scale: defining the path forward for research and practice. (2007) (32)
Bone marrow cell transfer in acute myocardial infarction (2006) (32)
Migration of two venous stents into the right ventricle in a patient with May-Thurner syndrome. (2006) (31)
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 (2019) (31)
Pharmacokinetics and Coronary Thrombolytic Properties of Two Human Tissue‐Type Plasminogen Activator Variants Lacking the Finger‐Like, Growth Factor‐Like, and First Kringle Domains (Amino Acids 6–173) in a Canine Model (1990) (31)
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. (2011) (31)
Polypill Strategy in Secondary Cardiovascular Prevention. (2022) (31)
Homograft survival after tetralogy of Fallot repair: determinants of accelerated homograft degeneration. (2007) (31)
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. (2010) (31)
After Correcting for Worse Baseline Characteristics, Women Treated With Thrombolytic Therapy for Acute Myocardial Infarction Have the Same Mortalit and Morbidit as Men Except for a Higher Incidence of Hemorrhagic Stroke (1993) (31)
Predictors of all‐cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry (2018) (30)
Relation between different methods for analysing ST segment deviation and infarct size as assessed by positron emission tomography (2004) (30)
Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion (2015) (30)
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. (2011) (30)
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. (1999) (30)
Acute myocardial infarction: early diagnosis and management (1998) (30)
In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary Syndrome. (2019) (28)
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. (2005) (28)
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. (2010) (28)
Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. (2006) (28)
Prospective Evaluation Of The Length Of The Lower Common Pathway In The Differential Diagnoss Of Various Forms Of AV Nodal Reentrant Tachycardia (1998) (27)
Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection (2012) (27)
Reperfusion for ST-segment elevation myocardial infarction: an overview of current treatment options. (2002) (27)
Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. (2003) (27)
Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). (2014) (27)
Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study (2012) (26)
Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. (2002) (26)
Metallic surface treatment using electrochemical polishing decreases thrombogenicity and neointimal hyperplasia after coronary stent implantation in a porcine model (1997) (26)
Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry (2019) (26)
Intravenous bolus administration of recombinant tissue plasminogen activator to patients with acute myocardial infarction (1990) (25)
Large streamlined trials in cardiovascular disease. (2014) (25)
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). (2004) (25)
Implementing the new European Regulations on medical devices-clinical responsibilities for evidence-based practice: a report from the Regulatory Affairs Committee of the European Society of Cardiology. (2020) (25)
Peripheral Blood RNA Levels of QSOX1 and PLBD1 Are New Independent Predictors of Left Ventricular Dysfunction After Acute Myocardial Infarction (2019) (25)
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. (2004) (25)
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. (2003) (25)
Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. (2015) (25)
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. (2016) (25)
Effect of long term physical training on heart rate variability (1996) (25)
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. (2018) (24)
Thrombolysis for acute myocardial infarction. Why is there no extra benefit after hospital discharge? (1995) (24)
Evaluation of transmural myocardial deformation and reflectivity characteristics (2001) (24)
Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction. (1991) (24)
Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. (2001) (24)
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. (2013) (23)
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. (2007) (23)
Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged (2015) (23)
Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial (2021) (23)
Impact of Selection Bias on Estimation of Subsequent Event Risk (2017) (23)
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. (2012) (23)
Metallic Surface Treatment Using Electrochemical Polishing Decreases Thrombogenicity and Neointimal Hyperplasia of Coronary Stents (2000) (23)
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). (2007) (23)
Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs. (1991) (22)
Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate. (2001) (22)
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. (2013) (22)
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. (2004) (22)
Usefulness of high-frequency analysis of signal-averaged surface electrocardiograms in acute myocardial infarction before and after coronary thrombolysis for assessing coronary reperfusion. (1990) (22)
The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. (2009) (22)
PET "reversed mismatch pattern" early after acute myocardial infarction: follow-up of flow, metabolism and function (2001) (22)
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. (2006) (22)
Acquisition and processing of the radio-frequency signal in echocardiography: a new global approach. (1994) (22)
Outcomes from patients with multi‐vessel disease following primary PCI (2011) (21)
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events (2019) (21)
Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization (2015) (21)
Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). (2002) (21)
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials (2016) (21)
Coronary reperfusion by thrombolysis and early beta-adrenergic blockade in acute experimental myocardial infarction. (1989) (20)
Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes and their relation to outcome. (2007) (20)
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER (2014) (20)
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). (2014) (20)
Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. (2001) (20)
Transfer Times and Outcomes in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Interhospital Transfer for Primary Percutaneous Coronary Intervention: APEX-AMI Insights (2012) (20)
Use of Only a Regular Diagnostic His‐Bundle Catheter for Both Fast and Reproducible “Para‐Hisian Pacing” and Stable Right Ventricular Pacing (1997) (20)
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. (2005) (20)
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS (2018) (20)
On-line quantification of left ventricular function by automatic boundary detection and ultrasonic backscatter imaging. (1993) (20)
Drug-eluting stents in acute myocardial infarction. (2006) (19)
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. (2007) (19)
The relative rapidity of recanalization induced by recombinant tissue‐type plasminogen activator (r‐tPA) and TNK‐tPA, assessed with enzymatic methods (2000) (19)
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). (2014) (18)
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. (2014) (18)
Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study (2015) (18)
Relationship Between Arterial Access and Outcomes in ST‐Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study (2016) (18)
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). (2015) (18)
Comparison of a Synthetic Antithrombin III-binding Pentasaccharide and Standard Heparin as an Adjunct to Coronary Thrombolysis (1998) (18)
Thrombolytic therapy. State of the art. (2001) (18)
The European Heart Journal: a European journal with a global impact in cardiovascular medicine. (2004) (18)
Calculation of strain values from strain rate curves: how should this be done? (2000) (18)
New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? (2009) (18)
Patterns of use of heparins in ACS (2003) (18)
Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. (2013) (17)
Improving public health by improving clinical trial guidelines and their application (2017) (17)
Angiographic evolution of coronary atherosclerosis in non-operated patients. (1983) (17)
Reperfusion treatment in acute myocardial infarction in elderly patients. (2018) (17)
Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial (2010) (17)
Assessment of quality indicators for acute myocardial infarction management in 28 countries and use of composite quality indicators for benchmarking (2020) (17)
Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator. (1990) (17)
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. (2005) (17)
The EURO SHOCK Trial: Design, Aims and Objectives. (2020) (17)
Thrombolysis-induced coronary reperfusion causes acute and massive interstitial release of cardiac muscle cell proteins. (1997) (16)
Accelerated thrombin generation during conjunctive treatment of myocardial-infarction with t-pa and r-hirudin (cgp-39-393) (1995) (16)
Complete occlusion of the main left coronary artery. A clinical study. (1987) (16)
Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial (2014) (16)
Will oral antithrombin agents replace warfarin? (2004) (15)
The history of coronary reperfusion. (2014) (15)
Antithrombotic Therapy in Patients With Heart Valve Prostheses (2013) (15)
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. (2014) (15)
Inhibitors of the Platelet Thrombin Receptor: Will They Live up to Their Promises? (2011) (15)
The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. (2003) (15)
Stent‐based tempamine delivery on neointimal formation in a porcine coronary model (2006) (15)
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial (2012) (15)
The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction. (2001) (15)
Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines (2012) (15)
Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model. (2005) (15)
What is the frequency and functional and clinical significance of complex lesions in non-infarct-related arteries after fibrinolysis for acute ST-elevation myocardial infarction? (2006) (15)
Effects of Heparin and Hirudin (CGP 39393) on Thrombin Generation During Thrombolysis for Acute Myocardial Infarction (1995) (14)
Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). (2014) (14)
Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes. (1997) (14)
Segmental comparison between coronary angiography and positron emission tomography reveals low predictive value of epicardial flow for viability. (1998) (14)
In vivo comparison between two tip pressure transducer systems (1995) (14)
The relationship between meteorological conditions and index acute coronary events in a global clinical trial. (2013) (14)
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 (2015) (14)
Subsequent Event Risk in Individuals With Established Coronary Heart Disease (2019) (14)
Association between restoration of autonomic modulation in the native sinus node and hemodynamic improvement after cardiac transplantation1 (2002) (14)
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. (2006) (14)
Fibrinolysis or primary PCI in myocardial infarction. (2013) (14)
Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE) (2003) (14)
Robustness of integrated backscatter for myocardial tissue characterization. (1999) (14)
Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). (2009) (14)
Bolus fibrinolysis: risk, benefit, and opportunities. (2001) (14)
Aortic and mitral valve replacement in osteogenesis imperfecta. Report of a case. (1986) (13)
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. (2016) (13)
Stent-mediated methylprednisolone delivery reduces macrophage contents and in-stent neointimal formation (2005) (13)
CORONARY THROMBOLYSIS WITH INTRAVENOUSLY ADMINISTERED HUMAN PRO-UROKINASE IN DOGS (1985) (13)
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy (2016) (13)
Comparison of a low‐molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs (1995) (13)
Lessons Learned From a Clinical Trial (2004) (13)
Pharmacologic Reperfusion Therapy for Acute Myocardial Infarction (2002) (12)
Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? (2015) (12)
Dual antiplatelet therapy in high-risk patients (2007) (12)
Usefulness of transesophageal echocardiography in patients with hemodynamic deterioration late after cardiac surgery. (1993) (12)
Computer processing of echo-mechanocardiograms: methods and results. (1982) (12)
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. (2013) (12)
Right coronary artery originating from distal left circumflex: an unusual feature of single coronary artery. (1991) (12)
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial (2020) (12)
Resolution of ST-segment elevation in acute myocardial infarction — Early prognostic significance after thrombolytic therapy (1999) (12)
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial (2018) (12)
Silent left and right coronary artery - left ventricular fistulas: an unusual prominent Thebesian system. (1983) (12)
Thrombolytic therapy and acute aortic dissection. (1992) (12)
Cardiac transplantation in giant cell myocarditis. A case report. (1994) (12)
Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. (2003) (12)
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). (2008) (12)
Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (2017) (12)
Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome. (2010) (12)
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. (1999) (11)
Preliminary clinical results with pro-urokinase (1986) (11)
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction (2001) (11)
Coronary thrombolysis with tissue-type plasminogen activator (1985) (11)
Thrombolysis for acute myocardial infarction (1994) (11)
Coronary thrombolysis with K1K2PU, a chimeric tissue‐type and urokinase‐type plasminogen activator: A feasibility study in six patients with acute myocardial infarction (1993) (11)
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial (2018) (11)
An Automated Strategy for Bedside aPTT Determination and Unfractionated Heparin Infusion Adjustment in Acute Coronary Syndromes: Insights from PARAGON A (2002) (11)
Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase. (1993) (11)
Coronary thrombolysis and infarct sizes reduction following intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates (1984) (10)
Nonlinear propagation effects on broadband attenuation measurements and its implications for ultrasonic tissue characterization. (1999) (10)
Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery (2015) (10)
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS (2013) (10)
Intracoronary autologous bone marrow cell transfer after myocardial infarction: a double blind randomized and placebo controlled clinical trial (2004) (10)
Apparent pulse wave velocity in the canine superior vena cava. (1983) (10)
Ultrasonic strain and strain rate imaging for the assessment of regional myocardial function in mice (2004) (10)
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial. (2006) (10)
Fine-tuning the selection of a reperfusion strategy. (2006) (10)
[Myocardial-infarction and Thrombolysis] (1991) (10)
Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). (2014) (10)
Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. (1994) (10)
Towards a new order in cardiovascular medicine: re-engineering through global collaboration. (2010) (10)
Normalized first derivative ofthe left apex cardiogram in assessment of left ventricular function. (1976) (10)
Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI. (2007) (10)
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. (2005) (9)
Prevention of Cardiogenic Shock After Acute Myocardial Infarction. (2019) (9)
Fine-Tuning the Selection of a Reperfusion Strategy (2006) (9)
Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution (2007) (9)
Dabigatran versus warfarin in patients with mechanical heart valves: reply (2014) (9)
A virtual environment for the evaluation, validation and optimization of strain and strain rate imaging (2003) (9)
Intravascular low‐power red laser light as an adjunct to coronary stent implantation: Initial clinical experience (2000) (9)
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. (2013) (9)
Dabigatran in patients with mechanical heart valves. (2014) (9)
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis (2010) (9)
Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). (2018) (9)
The wealth of nations and the dissemination of cardiovascular research. (2013) (8)
Ventricular tachycardia as a complication of annular subvalvular ventricular aneurysm in a Caucasian woman. (1987) (8)
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. (2018) (8)
Meta-analysis of studies of patients in the United Arab Emirates with ST-elevation myocardial infarction treated with thrombolytic agents. (2010) (8)
The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. (2006) (8)
Calibrated apexcardiography and assessment of left ventricular dynamics in man. (1976) (8)
Post-traumatic infarction due to blunt chest trauma. Report of two cases. (1980) (8)
New data in treatment of acute coronary syndromes. (2001) (8)
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. (2011) (8)
Mind the Model: Effect of Instrumentation on Inducibility of Atrial Fibrillation in a Sheep Model (2002) (8)
Heart Rate and Heart Rate Variability in Healthy Volunteers: Is the Female Cardiac Autonomic Nervous System Cardioprotective? (1998) (8)
Experimental validation of a new quantitative method for the analysis of infarct size by cardiac perfusion tomography (SPECT) (1993) (8)
The Clinician as Investigator: Participating in Clinical Trials in the Practice Setting Appendix 1: Fundamentals of Study Design (2004) (8)
Overlapping Coronary Stents Result in an Increased Neointimal Hyperplasia: Insight from a Porcine Coronary Stent Model (2000) (8)
The current role of thrombolytic therapy in the treatment of acute myocardial infarction (1999) (8)
Thrombolysis with rt-PA in acute myocardial infarction: no additional benefit of immediate PTCA (1988) (8)
Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). (2002) (8)
Primary percutaneous coronary intervention for acute myocardial infarction: Is it worth the wait? The risk-time relationship and the need to quantify the impact of delay. (2011) (7)
The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients. (2020) (7)
New data in treatment of acute coronary syndromes. (2001) (7)
Short- and long-term outcomes of patients with electrocardiographic left ventricular hypertrophy after fibrinolysis for acute myocardial infarction. (2005) (7)
Assessment of the optimal atrioventricular delay in dual chamber-paced patients by a portable scintillation probe (VEST) (1996) (7)
Pilot-study of combined administration of ridogrel and alteplase in patients with acute myocardial-infarction (1991) (7)
Cardiac phantom measurement validating the methodology for a cardiac multi-centre trial with positron emission tomography (2002) (7)
The ideal fibrinolytic: can drug design improve clinical results? (1999) (7)
Mechanocardiographic assessment of left ventricular function in coronary artery disease. (1980) (7)
More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. (1996) (7)
Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial (2016) (7)
ASSENT-3: implications for future trial design and clinical practice. (2002) (7)
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar (2016) (7)
A Statement on Ethics from the HEART Group (2008) (6)
A case report of a patient with a large aneurysmatic coronary artery fistula. (2000) (6)
Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry (2013) (6)
Summary statement: EHRA Summit 2010 with the Participation of Central-Eastern European Countries: ‘ICD for Life’ Initiative—Fighting against Sudden Cardiac Death in Emerging Economies (2011) (6)
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (2018) (6)
Automated contour detection of the left ventricle in short axis view and long axis view on 2D echocardiograms (1990) (6)
Antibiotic therapy for coronary artery disease: can a WIZARD change it all? (2003) (6)
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (6)
Relationship between apexcardiogram, left ventricular pressure and wall stress. (1982) (6)
Comparison of angiographic methods for the assessment of the extent of experimental anterior myocardial infarction in dog hearts. (1990) (6)
ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. (2009) (6)
Relationship between community hospital versus pre-hospital location of randomisation and clinical outcomes in ST-elevation myocardial infarction patients: insights from the Stream study (2018) (6)
Transplantation of autologous bone marrow-derived stem cells in patients with ST-segment elevation myocardial infarction (2005) (6)
Are changes in myocardial integrated backscatter restricted to the ischemic zone in acute induced ischemia? An in vivo animal study. (2000) (6)
A new quantitative method for the analysis of cardiac perfusion tomography (SPET): validation in post-infarct patients treated with thrombolytic therapy (1993) (6)
TNK-tPA for Acute Myocardial Infarction: The Clinical Experience (1999) (6)
Hemodynamic correlates of the third heart sound (1981) (6)
Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry (2016) (6)
Obesity management: the cardiovascular benefits (2005) (6)
Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. (2011) (6)
Importance of measurements at or after the J-point for evaluation of ST-segment deviation and resolution during treatment for acute myocardial infarction. (2005) (6)
CardioScape mapping the cardiovascular funding landscape in Europe (2018) (6)
Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEACS. (2017) (6)
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. (2016) (6)
Cardiomyocyte-specific NOS3 Overexpression Protects Against Chronic Pressure Overload-induced LV Hypertrophy and Dysfunction (2004) (6)
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. (2007) (5)
Clopidogrel instead of prasugrel or ticagrelor after 1 month in stabilized ACS patients: back to square one for DAPT? (2017) (5)
Relationship between wall stress and the apexcardiogram. (1980) (5)
Segmentation of echocardiographic images using classification in the radiofrequency feature space (1995) (5)
Reduction of in-stent restenosis in porcine coronary arteries after local delivery of adenovirus encoding NOS3 (1999) (5)
A Knowledge-Based System For The Delineation Of The Coronary Arteries (1989) (5)
Influence of Short Atrioventricular Delay on Late Diastolic Transmitral Flow and Stroke Volume (1992) (5)
Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial. (1988) (5)
Inventory of European databases related to cardiovascular diseases. (2012) (5)
Efficacy and safety of ridogrel versus aspirin in coronary thrombolysis with alteplase for myocardial infarction (1992) (5)
Pre-hospital management of acute coronary syndrome patients in Belgium and Luxembourg and other Western European countries. (2016) (5)
Is there a change in myocardial nonlinearity during the cardiac cycle? (2001) (5)
Software package for echocardiographic quantification: Leuven (SPEQLE) (1996) (5)
Endogenous fibrinolysis in STEMI: important before and after primary PCI (2018) (5)
Tilt training: a new treatment for neurocardiogenic syncope (1998) (5)
A statement on ethics from the HEART Group (2009) (5)
Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction (2016) (5)
TIFAHR: Time- and Frequency Analysis of Heart Rate Variability in Unrestrained Rats (1998) (5)
Discharge timing and outcomes after uncomplicated non–ST‐segment elevation acute myocardial infarction (2018) (5)
Sunday, 26 August 2012 (2012) (5)
A nonsurgical porcine model of left ventricular dysfunction. Validation of myocardial viability using dobutamine stress echocardiography and positron emission tomography (2000) (5)
Non-vitamin K oral anticoagulants in adults with congenital heart disease: quod non? (2020) (5)
Why is there so much geographic variation in clinical outcome in international trials of fibrinolytic therapy (2001) (4)
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters. (1992) (4)
Primary PCI and the indistinct 120 min time limit. (2019) (4)
Optimal dosing of intravascular low-power red laser light as an adjunct to coronary stent implantation: insights from a porcine coronary stent model. (2001) (4)
Primary percutaneous coronary intervention not always the best reperfusion strategy? (2014) (4)
Arterial wall temperature following coronary stent implantation in pigs: the role of post-stent inflammation. (2003) (4)
Single-bolus tenecteplase and front-loaded alteplase remain equivalent afte rone year: follow-up results of the ASSENT-2 trial (2000) (4)
Global patterns of health care for acute coronary syndromes (2004) (4)
A Pressure-Flow Study In Dogs (1984) (4)
New thrombolytic strategies (1993) (4)
Year 2008 ESC ST-segment elevation myocardial infarction guidelines: implications for the interventional cardiologist—from evidence to recommendations and practice (2009) (4)
Sibrafiban. Point of view (1999) (4)
Prevalence and mechanism of streptokinase induced platelet aggregation (1989) (4)
Influence of moxaprindine treatment on ventricular arrhythmias occurring during maximal exercise stress testing. (1979) (4)
Comparison of predischarge dipyridamole echocardiography with exercise electrocardiography for the prediction of multivessel coronary-artery disease after uncomplicated acute myocardial-infarction (1992) (4)
ASSENT-3: implications for future trial design and clinical practice. (2002) (4)
Regional wall motion and coronary patency rate after intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA): long-term results (1986) (4)
Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure (2017) (4)
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. (2009) (4)
Value of apexcardiography for the timing of left ventricular events in man. (1978) (4)
Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications. (2010) (4)
Decade in review—acute coronary syndromes: Successes and future objectives in acute coronary syndrome (2014) (4)
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary (2019) (4)
Prediction of event-free survival after hospital discharge in acute myocardial infarction treated with tissue-plasminogen activator. (1994) (4)
Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease. (2010) (4)
Streptokinase...never again. (1999) (4)
Specific thrombin inhibitors ... only one tool of the antithrombotic armamentarium. (1999) (4)
Coronary Reperfusion in Patients with an Acute Myocardial Infarction following Intravenous Administration of Recombinant Staphylokinase (1994) (4)
Left ventricular function changes during pharmacological and physiological interventions and routine activities monitored in healthy volunteers by a portable radionuclide probe (VEST) (2005) (4)
Deformation imaging by ultrasound for the assessment of regional myocardial function (2003) (4)
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. (2008) (4)
The growing burden of cardiovascular disease. (2012) (4)
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. (2005) (4)
What do new lytics add to t-PA? (1999) (4)
Echo-mechanocardiographic assessment of cardiac dynamics (1979) (3)
Transporting STEMI patients for primary PCI: a long and winding road paved with good intentions? (2016) (3)
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial (2021) (3)
RUPTURED ANEURYSM OF THE SINUS OF VALSALVA INTO THE RIGHT ATRIUM. AN UNCOMMON CONGENITAL HEART DEFECT. (2003) (3)
Single bolus administration of polyethylene glycol-derivated cysteine-substitution variants of recombinant staphylokinase in acute myocardial infarction (1999) (3)
Treatment of Bifurcation Lesions Using a New Tubular Stent (1998) (3)
Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease. (2010) (3)
Mortality results in GUSTO (1993) (3)
Corrections needed to 2016 ESC and AHA guidelines on heart failure. (2017) (3)
Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality. (2021) (3)
Cardiology. Acute coronary syndromes: Virchow's triad revisited. (1996) (3)
High-grade immunoblastic sarcoma: an unusual type of a primary cardiac non-Hodgkin lymphoma. (1995) (3)
Acute coronary syndromes: Virchow's triad revisited (1996) (3)
Implementation of reperfusion therapy in ST-segment elevation myocardial infarction A policy statement from the Belgian Society of Cardiology (BSC), the Belgian Interdisciplinary Working Group on Acute Cardiology (BIWAC) and the Belgian Working Group on Interven-tional Cardiology (BWGIC) (2009) (3)
Coronary thrombolysis in baboons after intravenous administration of recombinant tissue-type plasminogen-activator (rt-pa) (1984) (3)
A knowledge-based system for the automatic quantification of stenotic lesions on angiograms (1990) (3)
Geometrical variations of the canine superior vena cava: Relationship between diameter, segment length and transmural venous pressure (1987) (3)
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. (2013) (3)
Thrombolysis for acute myocardial infarction. (1994) (3)
Recombinant staphylokinase for thrombolytic therapy (1997) (3)
Monday, 27 August 2012 (2012) (3)
Streptokinase...never again. (1999) (3)
Successful mitral valvuloplasty using the Inoue balloon in a patient with mitral stenosis associated with subvalvular fibrosis and reduced left ventricular inflow cavity: a case report. (1991) (3)
The year in cardiology 2014: acute coronary syndromes. (2015) (3)
Coronary thrombolysis indogswithintravenously administered humanpro-urokinase (1985) (3)
Circulating oxidized LDL is a useful marker for cardiovascular risk assessment (2001) (3)
810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction (2004) (3)
The relationship between regional integrated backscatter levels and regional strain (1999) (3)
Ablation of focally-induced atrial fibrillation: selective or extensive? (2003) (3)
Intracardiac heart rate variability of the native sinus node in heart transplant patients (1999) (3)
Managing ST-elevation myocardial infarction (2002) (3)
Intramural and intrapulmonary injection of chlamydia pneumoniae leads to coronary artery intimal proliferation in normal pigs (2000) (3)
TAFI levels in patients with acute myocardial infarction treated with thrombolysis (2005) (3)
ST-deviation reconstruction in missing leads on the 12-lead ECG: applicability in studies on ST-segment resolution during thrombolysis. (2003) (3)
Regional challenges and opportunities in cardiovascular research: The Russian Federation "SWOT" analysis. (2011) (2)
In-hospital outcomes associated with fibrinolytic and thienopyridine use in patients with ST-segment elevation acute myocardial infarction. The global registry of acute coronary events. (2009) (2)
Management of acute coronary syndromes (2006) (2)
Nonlinear propagation effects on broadband attenuation measurements (1998) (2)
Experimental generation of diastolic heart sounds (1978) (2)
Closed chest myocardial biopsies: clinical uses and related problems. (1986) (2)
Evolution of intracardiac heart rate variability of the native sinus node in heart transplant patients (1999) (2)
Robust strain rate estimation using two-dimensional cubic B-splines (2002) (2)
Influence of transmural pressure on retrograde pressure pulse transmission velocity in the canine superior vena cava. (1984) (2)
Early and late exercise capacity after acute myocardial infarction treated with recombinant tissue-plasminogen activator. (1994) (2)
Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians". (2012) (2)
Recommendations for an efficient and safe use of fibrinolytic agents (2014) (2)
Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. (2019) (2)
Selecting the most appropriate reperfusion therapy for acute myocardial infarction. How useful are guidelines (1996) (2)
Intravenous streptokinase during acute myocardial infarction. A prospective open study. (1988) (2)
Coronary thrombolysis with human tissue-type plasminogen activator produced by recombinant DNA technology (1983) (2)
In TIME-II: more than a study on lanoteplase. (2000) (2)
Adenoviral Gene Transfer of Human Constitutive Endothelial Nitric Oxide Synthase to Injured Coronary Arteries (1997) (2)
Complete coronary perfusion (TIMI flow 3) improves prognosis after myocardial infarction but not incomplete (TIMI 2) perfusion (1993) (2)
The genesis of the third heart sound (1982) (2)
Tilt training in malignant neurocardiogenic syncope (1998) (2)
Pilot study of combined administration of ridogrel and rt-PA in patients with acute myocardial infarction (AMI) (1991) (2)
Phonocardiography and external pulse recording (1986) (2)
Long-term follow-up results of tilt training in patients with recurrent neurocardiogenic syncope (2000) (2)
Association between restoration of autonomic modulation in the native sinus node (SN) after cardiac transplantation and haemodynamic improvement (1999) (2)
New thrombolytic strategies. (1993) (2)
Superoxide dismutase, infarct size and postischemic recovery of myocardial contra ctility and metabolism in dogs (1989) (2)
Viscoelastic properties of the ventricle and the genesis of the 3rd heart-sound (1981) (2)
Overlapping Coronary Stents Result in an Increased Neointimal Hyperplasia Response. Insight From a Porcine Coronary Stent Model (1998) (2)
Parametric study of the peak negative acoustic pressure distribution within the image plane of a phased array transducer (2001) (2)
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. (2013) (2)
Future Directions in the Treatment of Acute Myocardial Infarction (2006) (2)
Thrombolytic treatment of acute myocardial infarction (1994) (2)
Left-to-right shunting in common congenital heart defects: which patients are eligible for percutaneous interventions? (2003) (2)
Cardiogenic Shock Developing Within 48 Hours After Thrombolysis for Acute Anterior Myocardial Infarction may be Related to Hemorrhagic Cardiac Tamponade Without Rupture (1996) (2)
Long term spontaneous evolution of left ventricular function after experimental acute coronary occlusion. (1988) (2)
Placental growth factor increases regional myocardial blood flow and function in a new porcine model of chronic myocardial ischemia (2009) (2)
Reperfusion treatment in acute myocardial infarction in elderly patients. (2018) (2)
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial (2017) (2)
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. (2005) (2)
Cardiac troponins in acute coronary syndromes. (1996) (2)
Despite superoxide dismutase treatment, postischemic contractile dysfunction persists after 4 hrs of reperfusion (1988) (2)
A direct comparison between internally and externally measured left ventricular systolic time intervals. (1975) (2)
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy? (2017) (1)
Cardiogenic shock: a call for aggressiveness. (2000) (1)
Relationship between left ventricular wall stress and the calibrated apexcardiogram (1978) (1)
Prognostic implications of prominent R wave in electrocardiographic leads V1 or V2 in patients with acute coronary syndrome. (2014) (1)
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome. (2014) (1)
Reconstruction of echocardiographic sector images from digital radiofrequency data (1994) (1)
INCREASED CARDIAC EXPRESSION OF TIMP-1 AND TIMP-2 IS RELATED TO CARDIAC FIBROSIS AND DYSFUNCTION IN THE CHRONIC PRESSURE-OVERLOADED HUMAN HEART.: PD.7 (2005) (1)
Anticoagulation of pregnant women with mechanical heart valves: protecting mother or child? (2017) (1)
European Commissioners petitioned for clean air and reduced noise pollution. (2015) (1)
Intracoronary gene transfer efficacy: comparison of local delivery catheters in pigs (1998) (1)
Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes (2021) (1)
Myocardial tissue perfusion measured with PET after successful thrombolysis in patients with acute myocardial infarction (1993) (1)
Noninvasive determination of stiffness of the left ventricle by combined M-mode echo- and apexcardiography. An experimental method. (1983) (1)
Early and 3 months follow-up results in 22 adult patients undergoing percutaneous transvenous mitral valvuloplasty. (1990) (1)
Inhibitors of the platelet thrombin receptor: will they live up to their promises? (2011) (1)
Current challenges and directions in antithrombotic therapy. (2008) (1)
Current challenges and directions in antithrombotic therapy. (2008) (1)
A regular diagnostic His bundle catheter suffices for both fast and reliable -µparahisian pacing-ã and right ventricular pacing (1996) (1)
Coronary patency after thrombolysis. (1993) (1)
Initial single-centre experience with the intrasept articulating device for percutaneous closure of the patent foramen ovale (2004) (1)
The relationship between the longitudinal pressure gradient and the blood flow velocity in the canine superior vena cava. (1986) (1)
Planar vs tomographic quantitation of perfusion defects after thrombolytic therapy (1992) (1)
Attenuation and dispersion of pressure waves in the canine superior vena cava (1983) (1)
Cardiac Autonomic Function is Linked to Coping Style in Healthy Subjects. An Explanation for Individual Differences in Vulnerability to (Psychological) Stress (1998) (1)
Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia (2021) (1)
Critical analysis of non-invasive indices for assessing cardiac function (1977) (1)
Age dependency of regional systolic and early diastolic radial strain rates (2001) (1)
Acute coronary syndromes: Transport for PCI versus fibrinolysis—long-term data scrutinized (2010) (1)
[Implementation of reperfusion therapy in ST segment elevation myocardial infarction (STEMI). A policy statement from the Belgian Society of Cardiology and its working group of acute cardiology and interventional cardiology]. (2010) (1)
Is Culprit-Lesion-Only PCI in Cardiogenic Shock Still Better at 1 Year? (2018) (1)
Have international guidelines failed? International variation in the treatment of acute MI: results of the VALIANT trial (2004) (1)
Transition from chronic stunning to hibernation and further on to necrosis in a porcine model of chronic ischemia identified with PET (2001) (1)
Current clinical experience with staphylokinase in arterial thrombosis (2004) (1)
The role of percutaneous transvenous balloon mitral valvuloplasty in the treatment of patients with symptomatic mitral stenosis. (1992) (1)
No STEMI left behind. (2014) (1)
Cardiac function assessment by simultaneous calibrated apex-and echocardiography (1978) (1)
On the clinical value of calibrated apexcardiography (1976) (1)
An unexpected Q fever endocarditis. Report of a case. (1987) (1)
Evaluation of transmitral pressure gradients at different heart rates: divergent action of isoprenaline and atropine. (1990) (1)
Mechanical safety of the contact with the wall coronary thermography methods: Comparison with catheters and guidewires (2003) (1)
A Statement on Ethics from the HEART Group (2008) (1)
Heart Rate Variability (HRV) in heart transplant recipients: evidence of reinnervation ? (1994) (1)
Histological dedifferentiation associated with functional dedifferentiation identified with dobutamine stress in a pig model of chronic ischemia (2002) (1)
An open environment for quantitative analysis of left ventricular function using ultrasound images. (1995) (1)
Implications of the GUSTO trial for thrombolytic therapy. (1996) (1)
Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898]. (2017) (1)
Thrombo-embolic complication after streptokinase therapy of pulmonary emboli. (1988) (1)
The Future of Treatment for ST-Elevation Myocardial Infarction (2004) (1)
New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? (2009) (1)
Influence of short atrio-ventricular delay on late diastolic filling dynamics (1990) (1)
Nitric oxide inhalation decreases myocardial injury in a porcine model of cardiac ischemia and reperfusion (2005) (1)
An experimental study of left ventricular wall stress and its apexcardiogram (1978) (1)
Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock—Reply (2007) (1)
Reproducibility of exercise-induced ventricular premature beats. (1982) (1)
Tuesday, 28 August 2012 (2012) (1)
Abstracts selected for presentation at the XXth Congress of the European Society of Cardiology, August 22–26,1998, Vienna, Austria (1998) (1)
Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome. (2010) (1)
A selection of abstracts to be presented at the XIXth Congress of the European Society of Cardiology, together with the 32nd Annual General Meeting of the Association of European Paediatric Cardiologists August 24–28,1997, Stockholm, Sweden (1997) (1)
Cardiomyocyte-specific endothelial Nitric Oxide synthase overexpression limits left ventricular remodeling after myocardial infarction in mice (2002) (1)
Acute ST-Segment Elevation Myocardial Infarction: The Open Artery and Tissue Reperfusion (2005) (1)
An open environment for quantification of left ventricular function using ultrasound images (1993) (1)
The European Heart Journal: parting thoughts after 6 years of editorship. (2008) (1)
Percutaneous adenovirus-mediated gene transfer to reduce restenosis in porcine coronary arteries (1998) (1)
Infarct size reduction and recovery of systolic function following coronary thrombolysis (tissue-type plasminogen activator) combined with bWta adrenergic blockade (metoprolol) (1987) (1)
Coronary patency after thrombolysis (1993) (1)
The CardioScape Project. (2014) (1)
Dobutamine stress echo may not always accurately predict segment viability in chronic global IV ischemia: an experimental study (2002) (1)
Temperature of the arterial wall after stent implantation: The role of poststent inflammation (2002) (1)
QRS duration at rest predicts maximal exercise performance in adult patients with repaired tetralogy of Fallot (2002) (1)
Anticoagulant agents for Acute Coronary Syndromes (2013) (1)
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. (2013) (1)
Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets. (2013) (1)
Risk assessment and longterm survival after thrombolytic therapy (1993) (1)
Dual platelet thromboxane A2synthase inhibition/endoperoxide receptor blockade (Ridogrel) and/or aspirin enhance thrombolysis with rt-PA in canine coronary arteries (1991) (1)
Pulmonary veno-occlusive disease: report of a case. (1982) (1)
Mimecan is an essential regulator of extracellular matrix integrity after myocardial infarction (2010) (1)
Adenoviral Mediated NOS3 Gene Transfer in Porcine Coronary Arteries Reduces In Stent Restenosis (1999) (1)
Survival analysis and classification of death in patients under anti-arrhythmic treatment. (1998) (1)
Intracoronary transplantation of labelled mesenchymal stem cells post myocardial infarction is associated with increased angiogenesis but fails to enhance functional recovery (2005) (1)
Impact of surface electrochemical polishing on stent performance: insights from a porcine coronary model (1999) (1)
Effects of coronary reperfusion on left ventricular function and survival (1990) (1)
Intracoronary mesenchymal stem cell or endothelial progenitor cell transfer post myocardial infarction prevents negative remodeling but fails to enhance global functional recovery (2006) (1)
Volume reviewers (2014) (0)
Abstract 21: Transfer Times and Outcomes in ST-Elevations Myocardial Infarction Patients Undergoing Inter-Hospital Transfer for Primary Percutaneous Coronary Intervention: APEX-AMI Insights (2012) (0)
Synthetic AT III-binding pentasaccharide versus standard heparin as adjunct to thrombolysis (1996) (0)
Perivalvular extension detected by transesophageal echocardiography in patients with a definite diagnosis bases on the Duke Endocarditis Criteria (1998) (0)
Long-term anticoagulant treatment after myocardial infarction. A review. (1973) (0)
686 High frame rate 19 Bit resolution integrated backscatter cyclic variations in normal human myocardium (1999) (0)
Dabigatran for patients with a mechanical valve. (2012) (0)
Contractile reserve after rt-PA (1989) (0)
Acute Cardiovascular Care : The STREAM Trial * (2018) (0)
Transcatheter aortic valve implantation: Belgian results are similar to the European data of the SOURCE registry using the Edwards Sapien™ valve (2010) (0)
Hemodynamics associated with a right ventricular third heart sound (1985) (0)
Two-dimensional myocardial strain rate estimation using "snakes" (2001) (0)
[The variable effect of coronary reperfusion on survival and left-ventricular function: how do thrombolytics act?]. (1994) (0)
TECOS Finds Sitagliptin Does Not Increase Heart Failure Risk (2015) (0)
Comparison of hospital charges and health benefit between direct PTCA and accelerated t-PA for the treatment of acute myocardial infarction, in the Belgian cohort of the GUSTO IIb trial substudy (1997) (0)
A combined echocardiographic and phonocardiographic study on the genesis of diastolic heart sounds (1979) (0)
STREAM characterisation correction (2017) (0)
Sharing clinical trial data: desirable but achievable? (2017) (0)
Can the Risk of Sudden Death after myocardial infarction be predicted by simple clinical criteria? experience from the VALIANT trial (2004) (0)
Current thrombolytic agents : fibrin-specific (1995) (0)
New Thrombolytics: A Light at the End of the Tunnel? (1998) (0)
First clinical experience with a new tubular coronary stent (V-Flex). Clinical and angiographic results (1998) (0)
Increased Expression of Syndecan-1 Protects Against Cardiac Dilatation and Dysfunction After Myocardial Infarction Heart Failure (2007) (0)
Subjects Index, Vol. 26, Supplement 4, 1996 (1996) (0)
In TIME-II: more than a study on lanoteplase. (2000) (0)
CardioScape-II: the need to map cardiovascular funding patterns in Europe. (2020) (0)
Different time course of electrical remodelling with continuous vs. bursted high-rate atrial pacing results in different susceptibility for atrial fibrillation (1998) (0)
The MISSION! program. (2007) (0)
Increased risk of both mortality and morbidity with prior as well as current atrial fibrillation after myocardial infarction: results of VALIANT (2004) (0)
Cardias TIMP-1 and TIMP-2 expression: markers of interstitial fibrosis in patients with aortic stenosis (2004) (0)
Transseptal left-sided ablation via specially preformed long sheaths: a hard to beat approach. (1998) (0)
Specific thrombin inhibitors ... only one tool of the antithrombotic armamentarium. (1999) (0)
The effect of stenting on the arterial wall temperature. The role of inflammation (2002) (0)
The effects of radiographic contrast media on alteplase-induced thrombolysis in dogs (1997) (0)
Sibrafiban: A Viewpoint by Frans J. Van de Werf (1999) (0)
Nitric Oxide and Apoptosis in Heart Failure (2002) (0)
The disappearance of the physiological third heart sound with age (1984) (0)
Transient decrease of coronary flow reserve in viable postischemic myocardium: Vascular “stunning” (1987) (0)
Prevention of Cardiovascular Events in Patients With Diabetes (2017) (0)
Diagnostic work-up of cardiac amyloidosis. (2010) (0)
The effect of valsartan, captogril, or both on left ventricular size and function following high-risk MI: the VALIANT echo study (2004) (0)
456 Can ultrasound strain rate characterise acute ischaemia-induced systolic function changes in an experimental pig model? (1999) (0)
European Society of Cardiology European Affairs: bringing science to policy-makers. (2014) (0)
Nitric oxide inhalation detects residual pulmonary vasoreactivity in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome (2000) (0)
Effect of low power red laser light therapy on neointimal hyperplasia. Results from a porcine coronary stent model (2000) (0)
IMPACT OF A SWITCH FROM DUAL ANTIPLATELET THERAPY TO SINGLE ANTIPLATELET THERAPY IN DIABETES AND NON-DIABETES POST ACS: INSIGHTS FROM THE EPICOR AND EPICOR-ASIA STUDIES (2017) (0)
Long-term anticoagulant treatment after myocardial infarction. A review. (1973) (0)
Trends in reperfusion therapy for acute ST-segment elevation myocardial infarction in an academic percutaneous coronary intervention center in the metropolitan area of a developing country: insights from the Jakarta Acute Coronary Syndrome registry. (2020) (0)
Facilitated versus primary PCI for acute myocardial infarction – Authors' reply (2006) (0)
Coronary thrombolysis and reocclusion: Where do we stand? (1988) (0)
Managing ST elevation myocardial infarction (2002) (0)
Parametric study of peak negative pressure distribution and its relationship to bubble destruction (1999) (0)
Does adenosine limit myocardial necrosis after percutaneous coronary intervention? Results of the adeline pilot trial (2001) (0)
[The variable effect of coronary reperfusion on survival and left-ventricular function: how do thrombolytics act?]. (1994) (0)
Inhibition of proteinases prevents cardiac injury during viral myocarditis (2004) (0)
Early and Late Effects of rt-PA vs Placebo on Left Ventricular Function Measured by Nuclear Ventriculography (1993) (0)
688 The relationship between regional integrated backscatter levels and regional strain (1999) (0)
Pacemaker dependence in paced patients (1994) (0)
Delayed relaxation of the right and left ventricle diameter with aging (1985) (0)
687 Is there a cyclic variation in myocardial non-linearity during the cardiac cycle? Implications for stress strain measurements (1999) (0)
The new Editorial Board starts with a focus issue on thrombosis: a key player in many cardiovascular diseases (2020) (0)
Dobutamine-echocardiography early after acute myocardial infarction (1994) (0)
Enoxaparinof its Clinical Use in the Management of Acute Coronary Syndromes (2002) (0)
Comparison of local delivery catheters for intracoronary gene transfer in pigs (1998) (0)
Neither atenolol, nor alinidine, added to thrombolytic therapy, reduces the incidence of arrhythmias during the first 24 hours of acute myocardial infarction (1993) (0)
[Recommendations for management of acute chest pain. Report of the Belgium Interdisciplinary Working Group on Acute Cardiology]. (2002) (0)
Age, weight and sex differences in cardiac autonomic function of healthy individuals: assessment by time- and frequency domain measurements of heart rate variability (1996) (0)
Selecting the most appropriate reperfusion therapy for acute myocardial infarction. How useful are guidelines? (1996) (0)
The Scimitar syndrome: report of a case. (1983) (0)
Determinants of Left Ventricular Function Two Weeks and One Year After an Acute Myocardial Infarction (1995) (0)
Study of the no-reflow phenomenon by PET within 24 hours after successful thrombolysis (1994) (0)
[Implementation of reperfusion therapy in ST segment elevation myocardial infarction (STEMI). A policy statement from the Belgian Society of Cardiology and its working group of acute cardiology and interventional cardiology]. (2010) (0)
Evaluation of the slow pathway potential (Asp) during pacing from different atrial sites (1998) (0)
Volume Reviewers (2009) (0)
Quantitative assessment of the residual coronary stenosis after endogenous and rt-PA induced thrombolysis (1988) (0)
Safety of the "contact with the wall" coronary thermography methods. Comparison with standard catheters (2002) (0)
Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease? (2021) (0)
Decreased Global Longitudinal Strain in Diabetics With Preserved Ejection Fraction Post-Myocardial Infarction: A VALIANT Echo Sub-study (2009) (0)
Systematic right atrial angiography greatly facilitates isthmus ablation for typical atrial flutter (1998) (0)
New Thrombolytics: A Light at the End of the Tunnel? (1998) (0)
Acute phase treatment of myocardial infarction: selecting patients for thrombolysis (1998) (0)
Repeated tilt testing in patients with neurocardiogenic syncope (2001) (0)
Title Page / Table of Contents, Vol. 26, Supplement 4, 1996 (1996) (0)
New aspects of pharmacological reperfusion: from macro- to microlysis (2001) (0)
Mortality results in GUSTO. (1993) (0)
Doppler Echocardiographic Evaluation of Right Ventricular Function During Graded Nitric Oxide Inhalation in Heart Failure (1999) (0)
Why is there so much geographic variation in clinical outcome in international trials of fibrinolytic therapy? (2001) (0)
Percutaneous balloon mitral valve commissurotomy: analysis of procedures and database (1994) (0)
P-434 Long-term follow-up after heart transplantation: Does the human heart reinnervate? (2003) (0)
Coronary thrombolysis withrecombinant single- chain urokinase-type plasminogen activator in patients withacutemyocardial infarction (1986) (0)
Coronary thrombolysis with clot specific thrombolytic agents: tissue-type plasminogen activator and prourokinase (1985) (0)
Paradoxical undersensing of high atrial rates with increasing sensitivity in dual-chamber pacemakers (1999) (0)
Abstract 3464: Differential Effects of Progenitor Cell Populations on Myocardial Neovascularization and Left Ventricular Remodeling after Myocardial Infarction (2008) (0)
Nadroparin-Ca (Fraxiparine) vs standard heparin as adjunct to thrombolysis (1993) (0)
Spotlight: Frans Van de Werf, MD, PhD. Interview by Richard Hoey. (2008) (0)
Abstract (2003) (0)
Absence of micro-RNA 146a blunts the hypertrophic response upon cardiac pressure overload (2011) (0)
Effects of coronary thrombolysis combined with beta blockade on regional wall motion and infarct size in dogs (1987) (0)
Reinnervation after heart transplantation (2004) (0)
Mimecan promotes wound healing after myocardial infarction (2012) (0)
Fibrinolytic, antithrombotic, and antiplatelet drugs in acute coronary syndromes (2018) (0)
Treatment of long coronary dissections after complicated balloon angioplasty using a single long Freedom stent. Clinical and angiographic follow-up (1998) (0)
Acute ST-segment elevation myocardial infarction: current approach and the open artery (1998) (0)
Cardiovascular changes during tilt table testing before and during tilt training in patients with recurrent neurocardiogenic syncope (2001) (0)
A32-5 Preventive effect of ACE inhibitors and diuretics on atrial fibrillation development after atrial flutter ablation (2003) (0)
485 Inhibition of urokinase and matrix metalloproteinases prevents left ventricular hypertrophy and cardiac failure during hypertension (2004) (0)
The slowpathway potential (Asp) indicates the activation of an anatomical input to the atrioventricular node (1999) (0)
Late diastolic filling dynamics in complete AV block (1989) (0)
Tilt table training for neurocardiogenic syncope in pediatric patients (1999) (0)
Assessment of the effect of rt-PA on infarct size by scintigraphic and enzymatic methods (1988) (0)
Determinants of late left ventricular contractile functions after acute myocardial infarction (1991) (0)
General anaesthesia during radiofrequency catheter ablation procedures: help or handicap? (1998) (0)
Recognition of variations in the anatomy of the posterior isthmus, as revealed by right atrial angiography, leads to tailored ablation for typical atrial flutter with a high success rate (1998) (0)
Effects of complement inhibition by pexelizumab on myocardial infarction or death following cardiac surgery. A combined analysis of two multicenter, placebo-controlled, randomized trials (2004) (0)
Heart valve tissue-engineered matrices attenuate monocyte binding and procoagulant responses in human endothelial cell cultures exposed to S. aureus, S. sanguis and S. epidermidis (2012) (0)
Myocardial viscoelasticity in man (1984) (0)
Recombinant tissue-type plasminogen activator for acute myocardial infarction: must dose be indexed for body weight? (1988) (0)
Micro-RNA 146a: a new kid on the block in the pathophysiology of cardiac hypertrophy and hypertensive heart failure, and a promising therapeutic target (2012) (0)
The use of cardiac catheterization and coronary angioplasty post myocardial infarction in Europe: observations from the GUSTO I trial (1996) (0)
Chapter 42 Fibrinolytic, antithrombotic, and antiplatelet drugs in acute coronary syndrome (2010) (0)
Comparison between angiographic and mechanocardiographic methods for evaluation of cardiac function in man (1976) (0)
Terzic A and Nelson TJ Regenerative Medicine editorial to Dubois C and Arminan A JACC 2010 (2013) (0)
Variability of integrated backscatter: simulations and measurements in vitro (1997) (0)
522 Increased expression of syndecan‐1 protects against cardiac dilatation and dysfunction after myocardial infarction (2006) (0)
Programmable electrical stimulation for evaluation of active atrial transport function (1989) (0)
Discrepancies between endpoint results in clinical trials of thrombolytic therapy: the salvage paradigm revisited (1993) (0)
High resolution integrated backscatter in acute myocardial ischemia (1995) (0)
A new percutaneous porcine chronic myocardial ischemia model utilizing a reduction stent (2007) (0)
Relationship between A-V delay and stroke volume during normal heart rate (1989) (0)
Antibiotics and Coronary Heart Disease—Reply (2004) (0)
Clinical outcome of delayed elective angioplasty after thrombolytic therapy for acute myocardial infarction (1991) (0)
283 u‐PA‐inactivation or TIMP‐1‐overexpression prevents cardiac injury and dysfunction during acute viral myocarditis in mice (2004) (0)
Defibrillation threshold using different electrode configurations (1995) (0)
Adenoviral gene transfer of human constitutive endothelial nitric oxide synthase gene inhibits restenosis after angioplasty in porcine coronary arteries (1997) (0)
Long-term follow-up of patients with acute myocardial infarction treated with tissue-type plasminogen activator (1985) (0)
Circulating oxidized LDL and the assessment of cardiovascular risk (2000) (0)
Quantitative analyses of the infarct related coronary stenosis: a comparative study between a geometric and a densitometric approach. Evaluation of intra- and interobserver variability (1987) (0)
Radiofrequency ablation of the his bundle after mustard correction and wall stents for D-transposition of the great arteries (1995) (0)
Transseptal versus retrograde ablation for left-side accessory pathways: an old story with a new conclusion (1997) (0)
Acute coronary syndromes : a transition in treatment standards : proceedings of a symposium held at the XXIst Congress of the European Society of Cardiology, Barcelona, Spain, August 1999 (2000) (0)
New modes of platelet inhibition - is their application limited? (1998) (0)
Thrombolysis with single-chain prourokinase in acute myocardial infarction. Recent Advances and New Developments in Hemostaseology (1986) (0)
Left ventricular dimensions and function in normals: reproducibility of measurements with segmented multiphase gradient echo MRI (1993) (0)
Spectral analysis of atrial and venous pressure waves: Methods and results (2006) (0)
Can power spectral analysis be used as a noninvasive test to monitor cardiac allograft rejection (1994) (0)
Letters to the EditorLetter to the Editor (2007) (0)
Left ventricular function and coronary patency 3 months after intravenous tissue-type plasminogen activator treatment in patients with acute myocardial infarction (1987) (0)
Major ventricular arrhythmias in 244 patients with AMI, treated with thrombolysis (1993) (0)
Myxoma in de linker ventrikel (1997) (0)
Apexcardiogram: time and frequency analysis (1982) (0)
Early Diastolic Left Ventricular Rapid Filling: Computation and Experimental Study (1998) (0)
Coronary artery and femoral venous thrombolysis with infusion or bolus recombinant single chain urokinase (saruplase) in dogs (1990) (0)
Can dobutamine echocardiography distinguish necrotic from ischemic myocardium, early after myocardial infarction? (1995) (0)
AMI in Patients Presenting with Persistent ST-Segment Elevation 2008 (2012) (0)
Validation of a non‐surgical porcine coronary stenosis model resulting in viable dysfunctional myocardium. Evidence for chronic stunning (2000) (0)
Flow, pressure and sound relations during early systole (1982) (0)
International workshop on antithrombotic therapy for acute coronary syndromes. May 9-10, 1996, Como, Italy. (1996) (0)
Amiodarone and thyroid function tests (1994) (0)
Thrombolytic Therapy and Concomitant Antithrombotic Therapies (2012) (0)
Changing pattern of etiologic microorganisms in infective endocarditis: comparison of a retrospective study in the 80s and a prosptecive study in the 90s in a University Hospital (1996) (0)
Dabigatran Inferior to Warfarin in Patients with Mechanical Heart Valves (2013) (0)
INTRAVENOUS IIB/IIIA'S : OPEN QUESTIONS AND HOW THEY ARE BEING ADDRESSED (1999) (0)
Chapter 7 – Thrombolytic Therapy (2004) (0)
Angiographic findings following infusion or double-bolus administration of alteplase in acute myocardial infarction (1997) (0)
Assessment of the effect of rt-PA on ventricular function and on infarct size by scintigraphic and enzymatic methods (1988) (0)
Abstract 5419: Nitric Oxide For Inhalation Reduces Left Ventricular Remodeling After Myocardial Infarction In Pigs (2008) (0)
Clinical practice guide in the European Cardiology Society on the manner of acute myocardial infarcts in patients with persistent elevation of the ST segment (vol 62, pg e1, 2009) (2010) (0)
[Beta-blockers in cardiac insufficiency]. (1997) (0)
Outcome of myocardial infarction in the unselected population is vastly different from samples of eligible patients in large-scale clinical trials (2002) (0)
Transition from chronic stunning to hibernation and further on to necrosis in a porcine model of chronic ischaemia identified with positron emission tomography (2002) (0)
Tilt training for neurocardiogenic syncope in paediatric patients (1999) (0)
Calibration of left ventricular apexcardiogram. (1979) (0)
The Mediterranean League Against Thromboembolic Diseases / Spanish Society of Thrombosis and Haemostasis (1994) (0)
Fibrinolytics: Current indications and treatment modalities in the absence of mechanical reperfusion (2008) (0)
Antithrombotic agents in coronary artery disease (1994) (0)
Coronaire thrombolyse met pro-urokinase (single-chain urokinase, type plasminogen activator) (1987) (0)
Coronary thrombolysis by intravenous infusion of synergistic thrombolytic agents (1989) (0)
Measurement of Heart Rate Variability, Baroreceptor Reflex Sensitivity and Blood Pressure Variability in Conscious and Unrestrained Rats (1998) (0)
Drug-eluting stents in acute myocardial infarction. (2006) (0)
A simulation study on the influence of dispersion on nonlinear wave propagation [in US contrast imaging] (2000) (0)
Deceleration of mitral flow and the genesis of gallop sounds (1984) (0)
The effect of overlapping coronary stents on neointimal hyperplasia. Insight from a porcine coronary stent model (2000) (0)
Brief Rapid Communication Coronary Thrombolysis With Recombinant Staphylokinase in Patients With Evolving Myocardial Infarction (2005) (0)
Acute myocardial infarction (1991) (0)
Late pathologic remodelling in a porcine coronary stent model (1998) (0)
Diagnostic work-up of cardiac amyloidosis (2010) (0)
Acute myocardial infarction. (1995) (0)
Results of amiodarone treatment in malignant ventricular arrhythmias (1994) (0)
Determinants of transmitral inflow pattern 10–14 days after acute myocardial infarction (1995) (0)
European Society of Cardiology European Affairs: bringing science to policy-makers. (2014) (0)
Reduction of in-stent restenosis by adenoviral-mediated NOS3 gene transfer in porcine coronary arteries (1998) (0)
Acute coronary syndromes: Transport for PCI versus fibrinolysis--long-term data scrutinized. (2010) (0)
MicroRNA signatures in left ventricular hypertrophy (2013) (0)
Axial pressure gradient in the canine superior vena cava. (1986) (0)
A27-4 Response to tilt training in different types of neurally mediated syncope (2003) (0)
Current Clinical Experience in Arterial Thrombosis with Staphylokinase Steven Vanderschueren , D ~ sir ~ Collen , and (0)
Primary PCI not Always the Best Reperfusion Strategy? (2014) (0)
Combined TXA2 synthase/PGH2 endoperoxide receptor antagonism limits myocardial infarct size at doses enhancing coronary thrombolysis by streptokinase (1992) (0)
Orthostatic training: a new treatment for neurocardiogenic syncope (1998) (0)
12.5 Evidence for chronic stunning in a novel porcine coronary stenosis model validated with positron emission tomography (2001) (0)
Changing pattern of aetiologic microorganisms in infective endocarditis: comparison of a retrospective study in the 80s and a prospective study in the 90s (1997) (0)
Intramural injection of Chlamydia Pneumoniae leads to coronary artery intimal proliferation in normal pigs (2000) (0)
Failure of medicine: evolution of an atrial septal defect to an Eisenmenger syndrome. (2000) (0)
Continuous mixed venous oximetry during exercise in patients with congestive cardiomyopathy (1988) (0)
Primary balloon dilatation in coarctation of the aorta complicated by severe aortic insufficiency. (1998) (0)
Transmitral flow velocity during complete AV block (1989) (0)
Orthostatic training: a new treatment for cardioinhibitory syncope (1998) (0)
Evaluation of the effect of oversizing on vascular injury, thrombogenicity and neointimals hyperplasia using the magic wallstent in a porcine coronary model (1999) (0)
Bolus Fibrinolytic Therapy (2008) (0)
Non-invasive evolution of left ventricular function (1980) (0)
Abstract 2495: Long-term Safety and Efficacy of Autologous Bone Marrow-derived Stem Cell Transfer after Acute Myocardial Infarction (2006) (0)
Hemodynamic study and left ventricular ejection time in ventricular bigeminy at different coupling intervals. (1988) (0)
Plasma hirudin and aPTT levels in acute patients of the GUSTO-2A trial compared with hirudin levels and aPTT in volunteers with stable coronary disease (1994) (0)
Matrix metalloproteinases-1 and -9, new biomarkers of human cardiac allograft rejection (2008) (0)
Sharing clinical trial data: desirable but achievable? (2017) (0)
Passive elastic stiffness: correlation between an invasive and a non invasive index (1982) (0)
Comparison between invasive and non-invasive methods for evaluation of myocardial function (1976) (0)
Changes in QRS duration during exercise are associated with maximal exercise capacity and peak oxygen consumption in adults with repaired tetralogy of Fallot (2003) (0)
[Recommendations for the management of acute chest pain. Report of the Belgian Interdisciplinary Group on Acute Cardiology]. (2002) (0)
Heart rate variability is associated with quality of life and coping mechanisms (1996) (0)
Time course of left ventricular pressure and apexcardiogram during the isovolumic phases (1980) (0)
Reperfusion intervention in acute myocardial infarction (1992) (0)
A cardiology data base with emphasis on chronic coronary artery disease (1980) (0)
u-PA-Gene Inactivation or TIMP-1-Gene Transfer Impairs Cardiac Injury Caused by Viral Myocarditis in Mice (2002) (0)
FEASIBILITY STUDY OF A LIQUID FORMULATION OF RECOMBINANT STAPHYLOKINASE FOR CORONARY ARTERY THROMBOLYSIS (1998) (0)
The importance of temporary reperfusion after thrombolytic therapy for acute myocardial infarction (1991) (0)
A Statement on Ethics from the HEART Group (2010) (0)
The Effect of Valsartan, Captopril, or Both on Left Ventricular Size and Function Following High-risk Myocardial Infarction: the VALIANT Echo Study (2004) (0)
Intracardiac Heart Rate Variability (HRV) of the Native Sinus Node (NS) in Heart Transplants. A New Method to Assess the Restoration of Autonomic Function After Cardiac Transplantation (1998) (0)
Percutaneous Transvenous Mitral Valvuloplasty, Percutaneous Transluminal Coronary Angioplasty, and Coronary Thrombolysis Applied Successfully to One Patient (1991) (0)
Left ventricular wall stress and relation to pressure and apexcardiogram (1980) (0)
P-009 Gender difference in the response to tilt testing (2003) (0)
Early Fibrinolysis as Effective as Primary PCI When Reperfusion Delay is Long (2013) (0)
Antibiotics and coronary heart disease. Authors' reply (2004) (0)
402 Do cyclic variations in integrated backscatter levels correlate with regional wall velocities in normal myocardium? A doppler myocardial imaging study (1999) (0)
Authors Index, Vol. 26, Supplement 4, 1996 (1996) (0)
Diagnostic value of plasma levels of oxidized LDL and of MDA-modified LDL in the assessment of stable angina and of acute coronary syndromes (1998) (0)
Influence of nitroglycerine on systolic time intervals (1979) (0)
Drug-eluting stents in primary PCI - Reply (2006) (0)
Evaluation of drug efficacy on ventricular arrhythmias during exercise (1980) (0)
Evaluation of myocardial viability with dobutamine stress echocardiography and PET in a porcine model of chronic ischemia (2000) (0)
Implications of the GUSTO Trial for Thrombolytic Therapy (1996) (0)
Differentiating various forms of AV nodal reentrant tachycardia based on the length of the lower common pathway (1997) (0)
Timing, quantification and prevention of bone loss after heart transplantation (1994) (0)
1095-203 Responsiveness to inhaled nitric oxide is related to mid-term survival in patients with congenital heart disease and obstructive pulmonary hypertension (2004) (0)
Abstract 3615: Placental Growth Factor Increases Regional Myocardial Blood Flow and Function in a New Porcine Model of Chronic Myocardial Ischemia (2009) (0)

This paper list is powered by the following services:

Frans Van de Werf's Academic­Influence.com Rankings

Why Is Frans Van de Werf Influential?

Frans Van de Werf's Published Works

Published Works

Other Resources About Frans Van de Werf

Frans Van de Werf's AcademicInfluence.com Rankings